These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
120 related items for PubMed ID: 3469323
1. Synthetic vaccines against Friend murine leukaemia virus-induced erythroleukaemia: in vivo and in vitro studies with synthetic oligopeptides and sequence-specific antisera. Bayer H, Hunsmann G. J Gen Virol; 1987 Feb; 68 ( Pt 2)():515-22. PubMed ID: 3469323 [Abstract] [Full Text] [Related]
2. Immunoprevention of Friend leukaemia virus-induced erythroleukaemia by vaccination with aggregated gp70. Kleiser C, Schneider J, Bayer H, Hunsmann G. J Gen Virol; 1986 Sep; 67 ( Pt 9)():1901-7. PubMed ID: 2427646 [Abstract] [Full Text] [Related]
3. Structural and immunological characterization of Friend murine leukaemia virus glycopolypeptide using synthetic oligopeptides. Bayer H, Gruber W, Schneider J, Hunsmann G. EMBO J; 1984 Aug; 3(8):1925-30. PubMed ID: 6479153 [Abstract] [Full Text] [Related]
4. Restriction of Friend virus-induced erythroid cell proliferation by CD4+ T-lymphocytes that recognize a single gp70 epitope. Miyazawa M, Fujisawa R. Leukemia; 1997 Apr; 11 Suppl 3():227-9. PubMed ID: 9209349 [Abstract] [Full Text] [Related]
5. Immunization with a single T helper cell epitope abrogates Friend virus-induced early erythroid proliferation and prevents late leukemia development. Miyazawa M, Fujisawa R, Ishihara C, Takei YA, Shimizu T, Uenishi H, Yamagishi H, Kuribayashi K. J Immunol; 1995 Jul 15; 155(2):748-58. PubMed ID: 7541823 [Abstract] [Full Text] [Related]
6. T-lymphocyte priming and protection against Friend leukemia by vaccinia-retrovirus env gene recombinant. Earl PL, Moss B, Morrison RP, Wehrly K, Nishio J, Chesebro B. Science; 1986 Nov 07; 234(4777):728-31. PubMed ID: 3490689 [Abstract] [Full Text] [Related]
7. Induction of feline leukaemia virus-neutralizing antibodies by immunization with synthetic peptides derived from the FeLV env gene. Weijer K, Pfauth A, van Herwijnen R, Jarrett O, Meloen RH, Tomee C, Osterhaus AD. Vaccine; 1993 Nov 07; 11(9):946-56. PubMed ID: 7692683 [Abstract] [Full Text] [Related]
8. In vitro growth inhibition of murine leukemia cells by antibody specific for the major envelope glycoprotein (gp71) of Friend leukemia virus. Genovesi EV, Collins JJ. J Cell Physiol; 1983 Nov 07; 117(2):215-29. PubMed ID: 6630299 [Abstract] [Full Text] [Related]
9. Susceptibility of Friend virus antigen-modulated erythroleukemic cells to lysis by T lymphocytes from mice with dormant Friend virus infections. Genovesi EV, Marx PA, Wheelock EF. J Immunol; 1979 Mar 07; 122(3):795-800. PubMed ID: 312825 [Abstract] [Full Text] [Related]
10. Different H-2 subregions influence immunization against retrovirus and immunosuppression. Morrison RP, Earl PL, Nishio J, Lodmell DL, Moss B, Chesebro B. Nature; 1979 Mar 07; 329(6141):729-32. PubMed ID: 2823142 [Abstract] [Full Text] [Related]
12. Approach to a retrovirus vaccine: immunization of mice against Friend virus disease with a replication-defective Friend murine leukemia virus. Ruan KS, Lilly F. Proc Natl Acad Sci U S A; 1992 Dec 15; 89(24):12202-6. PubMed ID: 1465459 [Abstract] [Full Text] [Related]
13. Use of adoptive transfer and Winn assay procedures in the further analysis of antiviral acquired immunity in mice protected against Friend leukemia virus-induced disease by passive serum therapy. Genovesi EV, Pettey CL, Collins JJ. Cancer Res; 1984 Apr 15; 44(4):1489-98. PubMed ID: 6608407 [Abstract] [Full Text] [Related]
14. Virus neutralizing and enhancing epitopes characterized by synthetic oligopeptides derived from the feline leukaemia virus glycoprotein sequence. Nick S, Klaws J, Friebel K, Birr C, Hunsmann G, Bayer H. J Gen Virol; 1990 Jan 15; 71 ( Pt 1)():77-83. PubMed ID: 1689371 [Abstract] [Full Text] [Related]
15. Protection against Friend retrovirus-induced leukemia by recombinant vaccinia viruses expressing the gag gene. Miyazawa M, Nishio J, Chesebro B. J Virol; 1992 Jul 15; 66(7):4497-507. PubMed ID: 1534853 [Abstract] [Full Text] [Related]
16. Immunotherapy of murine leukemia. IX. The requirement for the Fc portion of antibody for successful passive serum therapy of Friend leukemia virus-induced disease. Collins JJ, Sackie DM, Johnson GR. Virology; 1983 Apr 15; 126(1):259-66. PubMed ID: 6573816 [Abstract] [Full Text] [Related]
17. Peptide-induced immune protection of CD8+ T cell-deficient mice against Friend retrovirus-induced disease. Kawabata H, Niwa A, Tsuji-Kawahara S, Uenishi H, Iwanami N, Matsukuma H, Abe H, Tabata N, Matsumura H, Miyazawa M. Int Immunol; 2006 Jan 15; 18(1):183-98. PubMed ID: 16352628 [Abstract] [Full Text] [Related]
18. Resistance against Friend leukemia virus-induced leukemogenesis in DNA-dependent protein kinase (DNA-PK)-deficient scid mice associated with defective viral integration at the Spi-1 and Fli-1 site. Hasegawa M, Yamaguchi S, Aizawa S, Ikeda H, Tatsumi K, Noda Y, Hirokawa K, Kitagawa M. Leuk Res; 2005 Aug 15; 29(8):933-42. PubMed ID: 15978944 [Abstract] [Full Text] [Related]
19. Immunoglobulins in human serum reactive with murine Friend leukaemia virus. Bendinelli M, Toniolo A, Matteucci D, Celeste F, Revoltella R. J Gen Virol; 1980 Feb 15; 46(2):311-24. PubMed ID: 6155429 [Abstract] [Full Text] [Related]
20. Immunotherapy of murine leukemia. XI. differential susceptibility of spleen cells from serum-protected mice to the in vitro immunosuppressive effects of Friend leukemia virus-infected splenocytes. Pettey CL, Collins JJ. Int J Cancer; 1984 Aug 15; 34(2):269-76. PubMed ID: 6540757 [Abstract] [Full Text] [Related] Page: [Next] [New Search]